#### 1 Mycobiome Dysbiosis and Genetic Predisposition for Elevated IL-17A Drive Fibrosis in

#### 2 MASLD

- Nadja Thielemann<sup>1,†</sup>, Sara Leal Siliceo<sup>2,†</sup>, Monika Rau<sup>3</sup>, Annika Schöninger<sup>1</sup>, Nathalie Reus<sup>1</sup>, 3
- Alexander M. Aldejohann<sup>1,7</sup>, Aia Shehata<sup>1,4</sup>, Isabell S. Behr<sup>1</sup>, Natalie E. Nieuwenhuizen<sup>1</sup>, 4
- Michaela Herz<sup>1</sup>, Heike M. Hermanns<sup>3</sup>, Mohammad Mirhakkak<sup>2</sup>, Jürgen Löffler<sup>5</sup>, Thomas 5
- Dandekar<sup>6</sup>, Kerstin Hünniger-Ast<sup>1,4</sup>, Ronny Martin<sup>1</sup>, Gianni Panagiotou<sup>2,8,9,+,\*</sup>, Andreas 6

Geier<sup>3,+</sup>, Oliver Kurzai<sup>1,4,7,+,\*</sup> 7

#### 8 Affiliations

- 9 <sup>1</sup>Institute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany
- 10 <sup>2</sup>Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll 11 Institute, Jena, Germany
- 12 <sup>3</sup>Department of Medicine II, Division of Hepatology, University Hospital Würzburg, Germany
- 13 <sup>4</sup>Research Group Fungal Septomics, Leibniz Institute for Natural Product Research and Infection Biology - Hans 14 Knöll Institute, Jena, Germany
- 15 <sup>5</sup>Department of Internal Medicine II, University Hospital Würzburg, Germany
- 16 <sup>6</sup>Functional Genomics & Systems Biology, Department of Bioinformatics, University Würzburg, Germany
- 17 <sup>7</sup>National Reference Center for Invasive Fungal Infections, Leibniz Institute for Natural Product Research and
- 18 Infection Biology- Hans Knöll Institute, Jena, Germany
- 19 <sup>8</sup>Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany
- 20 <sup>9</sup>Department of Medicine, The University of Hong Kong, Hong Kong S.A.R., China
- 21
- 22 <sup>†</sup> These authors contributed equally
- 23 <sup>+</sup> These authors contributed equally
- 24
- \*Correspondence: Gianni.Panagiotou@leibniz-hki.de (G.P.), 25
- okurzai@hygiene.uni-wuerzburg.de (O.K.) 26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 27 ABSTRACT

28 Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of 29 chronic liver disease in Western countries. Progression to metabolic dysfunction-associated 30 steatohepatitis (MASH) occurs when fat accumulation in the liver triggers Th17 activation and 31 other inflammatory processes. In this study, we identify the IL17A rs2275913 minor allele 32 variant as a risk factor for fibrosis progression in MASLD patients. In patients with advanced 33 fibrosis, we also observed an increased abundance of fungal CTG species including *Candida* 34 albicans and Debaryomyces hansenii, which are potent triggers of Th17 responses. Integrating 35 genetic risk-predisposition and mycobiome composition, we show in *ex vivo* T cell stimulation assays, that donors carrying the minor allele variant of *IL17A* rs2275913 secreted significantly 36 37 higher IL-17A levels in response to CTG species. Additionally, MASH patients carrying the IL17A rs2275913 risk allele have elevated Th17/Treg ratios in peripheral blood. Taken together, 38 39 our data indicate that genetic predisposition for enhanced Th17 responses in the context of 40 mycobiome dysbiosis can trigger MASH progression and liver fibrosis.

# 41 Graphical Abstract



42 This Graphical Abstract was created with BioRender.com.

# 43

- 44 Keywords: mycobiome, intestinal fungi, Th17 signaling, IL-17A, MASLD, MASH, *Candida*,
- 45 liver fibrosis, liver inflammation

46

# 47 Brief summary

48

Increased antifungal immune responses triggered by gut mycobiome dysbiosis in genetically
 predisposed patients can lead to severe stages of metabolic dysfunction-associated steatotic

51 liver disease.

## 53 INTRODUCTION

54 Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease [NAFLD, (1)]) has become one of the leading causes of chronic 55 56 liver diseases, with a global prevalence of approximately 25% (2). MASLD is characterized by 57 the accumulation of excess fat in the liver in the absence of relevant alcohol consumption and 58 commonly associated with obesity, type 2 diabetes and metabolic syndrome (3). Fat 59 accumulation in hepatocytes leads to bland steatosis (BS), the initial step of MASLD 60 pathogenesis (4). Continued fat accumulation and lipotoxicity trigger inflammation and the transition to metabolic dysfunction-associated steatohepatitis (MASH). These inflammatory 61 62 processes lead to the development of fibrosis which may ultimately progress to cirrhosis (5). The reasons why some patients progress to MASH and others do not remain unclear, though 63 evidence suggests that exaggerated Th17 responses are associated with progression to MASH 64 65 (6).

66 The liver receives approximately 75% of its blood supply via the portal vein and therefore has close connection to the human intestinal tract, which is densely colonized by 67 68 microorganisms collectively known as the microbiome (7). Gut microbiota dysbiosis has been repeatedly observed in obesity and type 2 diabetes mellitus (8, 9). Recent data provide clear 69 70 evidence that the composition of gut microbiota also has a direct impact on MASLD 71 pathogenesis (10-13). Previously, we identified a significantly higher abundance of short chain 72 fatty acid (SCFA)-producing bacteria such as Fusobacteriaceae, Prevotellaceae, and 73 Ruminococcaceae in the gut of patients with advanced MASLD (14).

In contrast to the bacterial microflora, the role of intestinal fungi in MASLD is less well
 understood. Mycobiome research faces several challenges, including non-standardized

76 protocols, technical difficulties and incomplete reference databases (15, 16). A key challenge 77 is the unresolved taxonomy of the polyphyletic genus Candida, which comprises relevant human gut mycobionts that are only distantly related. Within the genus Candida, the CTG 78 79 species, which translate the CTG codon predominantly to serine instead of leucine, are of 80 special importance in human gut colonization. CTG species comprise both opportunistic 81 pathogens (e.g. *Candida albicans*) and non-pathogenic species (e.g. *Debaryomyces hansenii*) 82 (17). C. albicans is a major human mycobiont and has been shown to be a direct inducer of 83 human antifungal Th17 cell responses (18). Cross-reactivity to C. albicans induces Th17 84 responses to other fungi and plays an important role in airway inflammation, especially during 85 acute allergic bronchopulmonary aspergillosis. Thus, immune activation triggered by C. albicans may represent a key mechanism driving Th17 responses with broad systemic 86 87 impact (18).

Recently, Demir *et al.* characterized a distinct fecal mycobiome signature in non-obese
MASLD patients with *Malassezia* spp. abundance increased in patients with BS and *C. albicans*and *Penicillium* spp. abundance elevated in MASH patients. Notably, increased intestinal *C. albicans* colonization was associated with increased levels of systemic antibodies against *C. albicans* and advanced fibrosis (19). Furthermore, the presence of *C. albicans* specific Tcells in the liver has been demonstrated in alcohol-associated liver disease (ALD) (20).

The aim of our study was to investigate the role of the gut mycobiota in MASH in the context of intrinsic variations in IL-17A signaling. Our results identify a novel *IL17A* genetic risk variant for liver fibrosis in MASH and show that intestinal colonization with *C. albicans* and related species (CTG species) can contribute to enhanced inflammation in the presence of this genotype.

#### 99 **RESULTS**

#### 100 **Study population**

A total of 482 European subjects were recruited for this study, including 230 histology-proven MASLD patients (89 BS and 141 MASH). **Fig. 1** illustrates the clinical and histological phenotypes of the study participants in a flow diagram. Stool samples could be collected from a sub-cohort of subjects (42 BS, 79 MASH, 100 MASLD). As an additional control, a group of healthy individuals (HC) was included. Patients with and without 6 months antibiotic-free intervals were analyzed separately.

107

#### 108 Genetic variation in IL17A predisposes patients to develop fibrotic MASLD

109 Th17 responses and IL-17A signaling are known to play a key role in MASH related 110 inflammation (6). To further investigate genetic factors governing Th17 activation in our 111 patient cohort, we focused on analyzing relevant SNPs. As a preliminary step, we first validated the association of the PNPLA3 rs738409 genotype with liver fibrosis assessed by fibroscan 112 113 values for the dataset available for our patient cohort (21) as it is a major genetic risk factor for MASLD (22) (pKruskal-Wallis=0.105; pglm=0.028; glm adjusted; Fig. 2A). Subsequently, all 114 consecutive SNP-based glm calculations for the SNPs analyzed in this study were adjusted for 115 116 the PNPLA3 rs738409 risk genotype.

In an extensive dbSNP database search for genetic variants in Th17 signaling-associated genes linked to gastrointestinal disease with inflammatory properties, we identified three potential candidate SNPs. No significant association with MASLD disease parameters was found for rs16910526 (*CLEC7A* gene, coding for Dectin-1) and rs4077515 (*CARD9*) (**Suppl. Fig. 1**). Our

121 third candidate SNP was the IL17A rs2275913 SNP. This SNP was previously shown to be 122 associated with inflammatory bowel disease (23). TaqMan SNP genotyping of our 451-patient 123 MASLD cohort identified 175 G/G (homozygous for major allele variant, 38.8%), 55 A/A 124 (homozygous for minor allele variant, 12.2%), and 221 A/G (heterozygous, 49%) genotypes (Fig. 2B). Genotype frequencies were in Hardy-Weinberg equilibrium and selection for specific 125 126 genotypes was excluded (Suppl. Fig. 2). The calculated minor allele frequency (MAF) of 127 36.7% is comparable to the published ALFA European cohort MAF of 34.85%. Statistical 128 analysis revealed a significant association between the IL17A rs2275913 genotype and liver 129 fibrosis assessed by fibroscan (p<sub>Kruskal-Wallis</sub>=0.368; p<sub>glm</sub>=0.029; generalized linear model (glm) 130 adjusted; Fig. 2C). Patients carrying the minor allele (A/A & A/G) showed increased liver 131 stiffness and more severe fibrosis compared to those with a homozygous major allele genotype 132 (G/G).

133

#### 134 A distinct mycobiome composition characterizes MASH patients

135 Intestinal colonization by C. albicans is a major inducer of Th17 responses (18) and prior data 136 suggested altered mycobiome composition in subgroups of MASLD patients, potentially 137 linking mycobiome dysbiosis to Th17 activation (19). Thus, we analyzed mycobiome 138 composition using ITS1 libraries for 145 subjects from our study cohort to estimate the fungal 139 genus and species abundance and explore the possible role of fungi in MASLD progression and 140 liver damage. On average, we generated 15,500 high-quality, non-chimeric reads per sample 141 and fungal annotation identified 29 genera and 223 species in total. Genus-level fungal profiles 142 showed that Saccharomyces, Penicillium, and CTG species were the topmost abundant fungal 143 colonizers among our study participants, at 16.7%, 16.1%, and 12.5%, respectively. We used

the CTG species group for genus clustering, as *Candida* is a polyphyletic genus comprising a large variety of phylogenetically distant species. Members of the CTG species found in our dataset are pathogenic *C. albicans, Candida tropicalis, Candida dubliniensis, Candida parapsilosis* and non-pathogenic *D. hansenii*. Although still commonly referred to as *Candida,* other species including *Nakaseomyces glabratus (Candida glabrata), Kluyveromyces marxianus* (formerly *Candida kefyr*) and *Pichia kudriavzevii* (formerly *Candida krusei*) are only distantly related to the CTG species and were analyzed separately (17, 24).

151 In total, 76 BS, MASH, and MASLD subjects in our cohort reported antibiotic use 152 within 6 months before the stool collection. As a recent study showed that antibiotics may have 153 a long-term influence on the mycobiome (25) we investigated whether antibiotics had a 154 noticeable impact on the gut mycobiome profiles of the different disease groups. We found that 155 the mycobiome alpha-diversity measured by the Shannon and Simpson index at genus level 156 was significantly increased in MASH subjects who had used antibiotics compared to the 157 antibiotic-free subjects (Wilcoxon rank-sum test, p<sub>Shannon index</sub>=0.028 and p<sub>Simpson index</sub>=0.025; 158 Suppl. Fig. 3). However, no differences were found in the BS and MASLD groups between 159 antibiotic and antibiotic-free subjects. Using Aitchison distance to compute beta-diversity, no 160 differences were found between the antibiotic and antibiotic-free subjects in any of the disease 161 groups (PERMANOVA adjusted for age, gender and obesity-related parameters, p>0.05). 162 Nevertheless, to avoid a possible impact of antibiotics on the downstream analysis, two 163 approaches were used for the mycobiome comparisons. For all the main results, unless 164 specified, a dataset with only the long-term antibiotic-free samples was used. Alternatively, 165 mycobiome analysis was performed using all samples, adjusting for antibiotic intake when 166 appropriate (see methods for details).

168 To study the mycobiome changes related to MASLD progression, we first performed 169 pairwise comparisons between BS, MASH, MASLD and HC in alpha diversity measured by 170 the Shannon and Simpson index and we found no significant differences between the four 171 diagnosed groups (Wilcoxon rank-sum test, p>0.05 for all pair group comparisons for Shannon 172 and Simpson index, data not shown). Beta diversity analysis using Aitchison distance to assess 173 the overall mycobiome community differences showed that the fungal composition was 174 significantly different between MASH and HC subjects (PERMANOVA adjusted for age, 175 gender and obesity-related parameters, p=0.01, Fig. 3A).

176 We then explored the differences in fungal abundance between the disease groups (BS, 177 n=31; MASH, n=64; MASLD, n=50) and healthy controls (HC, n=25). Again, fungi were 178 grouped according to genus, except for the CTG species group. The most abundant genus in 179 the HC group was *Penicillium* (22.2%), followed by *Saccharomyces* (20.9%), and CTG species 180 (12.2%) (Fig. 3B). Similar abundance patterns were observed for the BS and MASLD groups 181 (Fig. 3B). Interestingly, in MASH, the most abundant genus was the CTG species group 182 (17.8%), followed by Saccharomyces (14.1%) and Penicillium (12.5%) (Fig. 3B). Among the 183 most abundant genera, we found Saccharomyces abundance significantly decreased in BS and 184 MASH in comparison to HC (Wilcoxon rank-sum test, p<sub>HCvsBS</sub>=0.026, p<sub>HCvsMASH</sub>=0.027, Fig. 185 **3C**). In addition, *Penicillium* was significantly decreased in abundance in all disease stages in 186 comparison to HC even though it did not reach statistical significance in comparison to BS 187 (Wilcoxon rank-sum test, pHCvsMASH=0.038, pHCvsMASLD=0.023, pHCvsBS=0.051, Fig. 3C). 188 However, the statistical significance was lost for the two genera when accounting for age, 189 gender, and obesity-related parameters (glm adjusted, p>0.05, Fig. 3C), suggesting a potential 190 confounding effect in the abundances of the two genera by these factors.

191 We subsequently repeated all the analytical steps using the full cohort and not only the 192 antibiotic-free subjects and confirmed the significant differences in beta diversity between the 193 MASH and HC groups (PERMANOVA adjusted, p=0.034, Suppl. Fig. 4A) and the significant 194 decrease in abundance of *Penicillium* in the MASLD and MASH groups compared to HC 195 (phcvsMash=0.03, phcvsMasLd=0.02, Wilcoxon rank-sum test; phcvsMash=0.007, phcvsMasLd=0.42, glm 196 adjusted). Even though it did not reach statistical significance as it did when using the 197 antibiotic-free set of samples, the same trend was observed for Saccharomyces, having lower 198 abundance in the MASH and MASLD groups compared to HC (Wilcoxon rank-sum test, 199 phcvsmash and phcvsmasld < 0.1).

200 Finally, we used 16S data from our cohort in order to build a microbial community 201 network to identify possible associations between fungal and bacterial genera and MASLD 202 progression. Using all cohort samples, we built a community network using FastSpar (26), and 203 identified a total of 5,848 significant correlations (SparCC, p<0.05) from which 4,017 remained 204 significant after multiple testing correction (FDR correction, q<0.1). Using greedy modularity 205 optimization, a total of 4 subcommunities were identified in the full network (Fig. 3D). We 206 then studied the associations between these subcommunity modules and MASLD and identified 207 one module that consists of 2 fungal (CTG species group and Saccharomyces) and 9 bacterial 208 genera (including Ruminococcus, Dialister, and Parasutterella amongst others) that were 209 significantly associated with MASLD-related parameters (fibroscan, AST, ALT, and GGT) 210 (Fisher's Exact test, p=0.049, odds ratio=3.580), suggesting the interplay of the two microbial 211 kingdoms and MASLD.

#### 213 Increased abundance of CTG species in patients with advanced fibrosis

214 To investigate whether changes in the mycobiome composition are linked to progression of 215 liver fibrosis we classified the subjects into early or advanced fibrosis groups using a fibroscan 216 cut-off value of 9.7kPa (27). Alpha diversity analysis (Shannon and Simpson index) revealed 217 no significant differences at the genus level (Wilcoxon rank-sum test, p>0.05). However, beta diversity analysis using Aitchison distance showed significant differences in the mycobiome 218 219 composition between early and advanced fibrosis groups (PERMANOVA adjusted for age, 220 gender, and obesity-related parameters, p=0.007, Fig. 4A). Further exploration of the 221 mycobiome composition (Fig. 4B) revealed that CTG species were significantly increased in 222 the advanced compared to the early fibrosis group even when accounting for age, gender, and 223 obesity-related parameters (pwilcoxon=0.0009, Wilcoxon rank-sum test; pglm=0.002, glm 224 adjusted, Fig. 4C).

225 To further corroborate our findings, we calculated the beta diversity (Aitchison 226 distance) of early and advanced fibrosis groups using all subjects and not only the antibiotic-227 free subjects. Again, significant differences were identified (PERMANOVA adjusted, p=0.01, 228 Suppl. Fig. 4B) and a significant increase in CTG species abundance in advanced- compared 229 to early fibrosis (Wilcoxon rank-sum test, p<sub>wilcoxon</sub>=0.0007; glm adjusted, p<sub>elm</sub>=0.002) was also clearly visible when analyzing the full cohort (Suppl. Fig. 4C). Thus, in both antibiotic-free 230 231 and total study cohorts, CTG species abundance is significantly higher in the advanced fibrosis 232 group, suggesting that these species may contribute to disease progression.

233

Regression analysis between fibroscan stiffness values independent of the arbitrary cutoff of 9.7kPA and CTG species abundance also revealed a significant association (glm adjusted for age, gender, and obesity-related parameters, p=0.001, estimate=0.22). Correlation analysis

also showed a positive significant correlation between fibroscan values and CTG species abundances (Spearman's correlation adjusted, p=0.026,  $\rho$ =0.23). We also evaluated this association for the complete cohort and the same results were obtained (presence/absence of CTG species associated with the fibrosis stage, p=0.002, odds ratio=2.73, Fisher's Exact test; CTG species abundances and fibroscan, significant positive correlation, Spearman's correlation adjusted, p=0.01,  $\rho$ =0.20 and glm adjusted, p=0.002, estimate=0.23, accounting for age, gender, obesity-related parameters and antibiotic use).

Finally, the trend of increasing CTG species abundance was also visible when samples were grouped by fibrosis stage obtained by histology (**Suppl. Fig. 5**), although for fibrosis stages F3 and F4 the sample size was too small to reach statistical significance due to a lack of biopsied patients (Kruskal-Wallis, p=0.07 for the antibiotic-free sample set and p=0.086 for the full cohort). We further explored CTG species imbalance in an advanced fibrosis stage in the antibiotic-free set of samples and found an association between the presence/absence of the CTG species group and the fibrosis stage (Fisher's Exact test, p=0.006, odds ratio=3.097).

251

# 252 CTG species trigger increased pro-inflammatory responses in the presence of the *IL17A* 253 rs2275913 risk genotype

Our findings so far establish a new risk genotype in *IL17A* for progression of MASLD and confirm mycobiome dysbiosis in patients with advanced stage liver fibrosis. To determine whether the *IL17A* rs2275913 SNP has an impact on responses to CTG species, we stimulated freshly isolated T cells from rs2275913-genotyped donors *ex vivo* with fungal lysates. To ensure that differences in T cell proportions among peripheral blood mononuclear cells (PBMCs) of individual donors did not influence IL-17A levels, we first isolated T cells and then used equal

260 numbers of T cells in the ex vivo stimulation assays. An age-dependent influence on CD4+ T 261 cell frequency was excluded due to similar mean age of donors within the genotype groups 262 (mean values for donor age are between 30-31 years). T cells were stimulated with fungal 263 lysates of a pathogenic (C. albicans) and a non-pathogenic (D. hansenii) representative of the CTG species group as well as with the non-CTG species Saccharomyces cerevisiae. Resulting 264 265 levels of multiple Th17 signaling-associated cytokines were quantified using Luminex 266 technology. T cell functionality was measured after stimulation with anti-CD3/anti-CD28 and 267 did not show genotype-dependent differences validating all effects induced by fungal lysates 268 as species-specific. To account for medium-mediated activation effects, all samples were 269 normalized to the corresponding medium control values for each donor. Both CTG species 270 lysates triggered increased release of proinflammatory IFN- $\gamma$ , TNF- $\alpha$ , IL-22 and IL-17A 271 following ex vivo T cell stimulation especially in donors carrying the IL17A rs2275913 A allele 272 (Table 1). Cytokine levels were generally lower after T cell stimulation with the non-CTG 273 species S. cerevisiae in comparison to C. albicans and D. hansenii (Table 1). To further 274 characterize especially proinflammatory IL-17A release following ex vivo T cell stimulation of 275 rs2275913-genotyped donors, we additionally measured IL-17A release by highly sensitive 276 ELISA after calculation with a 4-parameter standard fit curve. Again, effective and rs2275913 277 genotype-independent T cell functionality was evaluated after stimulation with anti-CD3 278 (Suppl. Fig. 6A), and all samples were normalized to the corresponding medium control values 279 for each donor. T cells were stimulated with fungal lysates of pathogenic (C. albicans) and non-280 pathogenic (D. hansenii) representatives of the CTG species group (28, 29), a combination of 281 both stimuli as well as with the non-CTG species S. cerevisiae (Fig. 5). Both CTG species 282 lysates induced IL-17A secretion and T cells from individuals with the rs2275913 A/A 283 genotype showed significantly increased IL-17A levels in comparison to those with the

284 rs2275913 G/G and heterozygous genotypes (*C. albicans*: p<sub>Kruskal-Wallis</sub>=0.104, p<sub>A/AvsG/G</sub>=0.042; 285 D. hansenii:  $p_{Kruskal-Wallis}=0.065$ ,  $p_{A/AvsG/G}=0.035$ ; Fig. 5A+B). Interestingly, this effect was 286 even elevated when both fungal lysates were used as stimuli for T cells in half concentration 287 each ( $p_{Kruskal-Wallis}=0.019$ ,  $p_{A/AvsG/G}=0.019$ ; Fig. 5C), indicating a cumulative effect of antigens of these two species as seen before (18). Additionally, the strongly elevated IL-17A secretion 288 289 in donors with the rs2275913 A/A variant were not visible after T cell stimulation with non-290 CTG species S. cerevisiae (Fig. 5D) or pathogenic C. tropicalis, C. parapsilosis and N. 291 glabratus (Suppl. Fig. 6B-D). Thus, the IL17A rs2275913 genotype modifies the amount of IL-17A produced in response to specific CTG species. Together with the elevated CTG species 292 293 abundance in MASLD patients, this suggests a combinatory effect of a genetically determined 294 enhanced Th17 response and the imbalance in CTG species on fibrosis progression in patients 295 with MASH.

296

#### 297 MASH patients carrying the *IL17A* rs2275913 A allele have elevated Th17/rTreg-ratios

298 To further explore the potential predisposition of MASLD patients to develop MASH if they 299 carry the IL17A rs2275913 minor allele, we associated results from IL17A rs2275913 300 genotyping of MASLD patients to their blood Th17/resting regulatory T cells (rTreg) ratios. In 301 a previous work, we identified elevated Th17/rTreg-ratios especially in MASH patients in 302 comparison to healthy controls (6), which was also observed in the subset of patients enrolled 303 in this study (p<sub>MASHvsHC</sub>=0.00012, p<sub>Kruskal-Wallis</sub>=0.00016; Fig. 6A). *IL17A* rs2275913 genotyping 304 of these patients revealed that Th17/rTreg-ratios are significantly upregulated in carriers of the 305 A allele (p<sub>A/GvsG/G</sub>=0.033, p<sub>Kruskal-Wallis</sub>=0.066; **Fig. 6B**). Taken together with the results from *ex* 306 vivo stimulation assays, this indicates that MASLD patients may be predisposed to develop

- 307 MASH if they carry the *IL17A* rs2275913 A allele due to contribution of increased Th17/rTreg-
- 308 ratios as well as increased pro-inflammatory cytokine release to liver inflammation, particularly
- 309 in the presence of a dysbiotic mycobiome characterized by increased abundance of CTG
- 310 species.

#### 311 **DISCUSSION**

312 MASLD, formerly known as NAFLD, affects more approximately 25% of the global 313 population and as such constitutes a major public health challenge world-wide. Its pathogenesis 314 is multifactorial, involving multiple determinants like genetic predisposition, diet and 315 composition of the microbiota (30). In this study, we identify a link between genetic variation 316 in IL17A and the dysbiosis of the gut mycobiome as contributing factors to MASLD 317 progressions, particularly inflammation-dependent progression to MASH. Our previous 318 research showed that the progression from BS to MASH is marked by an increase in IL-17A-319 producing cells within intrahepatic CD4+ T cells and a higher Th17/rTreg ratio in peripheral 320 blood (6). Here, we found that patients with the *IL17A* rs2275913 minor allele (A/A genotype) 321 were at a higher risk of severe fibrosis, displayed elevated IL-17A secretion in response to 322 fungal stimuli, and had higher Th17/rTreg ratios.

323 The involvement of IL-17A in maintaining health during immune responses to 324 infection, injuries and physiological stress is well described (31). Importantly, IL-17A is also 325 crucial for the antifungal response of the adaptive immune system (32). However, if 326 dysregulated, this proinflammatory cytokine can contribute to the development of various 327 diseases including liver fibrosis (33). Dysbiosis of the intestinal mycobiome correlates with 328 inflammatory bowel disease as well as liver diseases (19, 34, 35). Our observations indicate 329 that both, genetic variation in IL17A and increased intestinal abundance of CTG species, may 330 have a combined effect to foster the progression of BS to MASH. This is in line with recently 331 published work characterizing the contribution of Th17 cells, which are specific to C. albicans, 332 to ALD indicating similar mechanisms for MASLD pathogenesis and especially MASH 333 development (20). On the other hand, increased C. albicans commensal gut colonization

positively correlates with systemic levels of fungal-specific Th17-driven inflammation and therefore might improve host defense against other pathogens (36). These observations clearly support the importance of a balanced antifungal IL-17A-mediated immunity for human health and disease that seem to be dysregulated in *IL17A* rs2275913 A/A predisposed MASLD patients and contributes to inflammatory-driven liver fibrosis.

339 The described increase of intestinal CTG species abundance in MASLD 340 patients, especially in those with advanced fibrosis, is similar to the elevated abundance of 341 C. albicans and Debaryomyces spp. found in the gut of alcohol abuse disorder patients (35). 342 The C. albicans-secreted exotoxin candidalysin is associated with the severity of liver disease 343 in ALD patients (37). Additionally, it was found that C. albicans strain diversity influences the 344 immune response in inflammatory bowel disease (38). Candidalysin might explain how highly 345 abundant intestinal C. albicans contribute to gastrointestinal and liver diseases. However, the 346 gene encoding this peptide is absent in most non-albicans CTG species, including D. hansenii 347 (28). Our experiments revealed that D. hansenii can similarly trigger IL-17A secretion 348 following ex vivo T cell stimulation, resulting in comparable cytokine levels as observed for C. 349 albicans. This finding indicates different immune recognition mechanisms for the several CTG 350 species that could culminate in comparable activation patterns of Th17 responses. This might 351 be similar to the different mechanisms of immune recognition discussed for closely related but 352 non-CTG species such as N. glabratus (39). Irrespective of the way of activation, elevated CTG 353 species-mediated IL-17A secretion may contribute to BS to MASH transition and is probably 354 enhanced in carriers of the IL17A rs2275913 A/A variant.

355 Mycobiome dysbiosis involving increased intestinal abundance of *D. hansenii* is of 356 particular interest, as this food-borne yeast is often found on cheese as well as processed meat

in Western-style diet and is therefore often seen as a transient mycobiome component. Although 357 358 the possible probiotic properties of *D. hansenii* have been studied intensively (40), its functional 359 role in the context of human disease is still unknown and needs to be characterized. Here, D. 360 hansenii was shown to possess a T cell stimulatory potential, that is enhanced in IL17A rs2275913 A/A-predisposed MASLD patients. Prior studies established that D. hansenii 361 362 contributes to impaired wound healing in Crohn's disease patients as well as in the 363 corresponding mouse model (41). If mice with elevated intestinal abundance of C. albicans and 364 / or *D. hansenii* underwent antifungal amphotericin B treatment, symptoms of impaired wound 365 healing and also diet-induced liver fibrosis and steatohepatitis improved (19, 41). Overall, these 366 data combined with our observations suggest that non-pathogenic CTG species are relevant for gut- and liver-related inflammatory diseases, especially in genetically predisposed IL17A 367 368 rs2275913 A/A patients.

369 Although our results corroborate the role of intestinal fungi, especially CTG species, 370 and antifungal Th17 responses in MASLD pathogenesis, there are some limitations. Our ITS1-371 based gut mycobiome analysis clearly confirmed recent data generated by ITS2 sequencing. 372 However, we cannot exclude that primer bias resulted in the omission of common mycobiome-373 associated species like Malassezia spp. in our data set (42). Due to the intestinal mycobiome 374 variability between and even within individuals, future longitudinal studies are essential to 375 exclude possible diet, antibiotic or environmental-mediated effects. These studies would further 376 reinforce causal intestinal mycobiome changes associated with MASLD pathogenesis. 377 Incorporating the bacterial influence on the interaction between CTG species and antifungal 378 Th17 responses in MASLD pathogenesis would be of interest for future studies. Although the 379 analysis of this triangle including human-fungal-bacterial interaction might be challenging 380 under *in vitro* conditions, our interaction analysis already predicted that CTG species and

381	SCFA-producing bacterial genera jointly contribute to liver pathology and MASLD
382	progression. The bacterial-derived SCFAs might act as soluble mediators in this interactome as
383	they were already linked to both, MASLD pathogenesis and increased intestinal abundance of
384	<i>C. albicans</i> , before (43, 44).
385	Altogether, our results provide deeper insights into the role of intestinal fungi in
386	MASLD pathogenesis as they suggest a combinatory effect of IL17A risk variant-driven

387 increased antifungal Th17 response and elevated intestinal CTG species abundance to drive

388 liver inflammation and progression to fibrosis, thereby promoting BS to MASH transition.

#### 389 **METHODS**

390

## 391 Patients (MASLD cohort)

392 In this prospective study, 451 MASLD patients were enrolled between 2016-2019 in 393 the Division of Hepatology of the Department of Medicine II, University Hospital Würzburg, 394 Germany. All study participants were >18 years old and diagnosed with MASLD by histology 395 (n=230) and/or clinically by transient elastography (TE; fibroscan and controlled attenuation 396 parameter (CAP) (n= 350). We included all clinically characterized MASLD subjects in our 397 cohort irrespective of histological characterization to investigate associations between genetic 398 variations in antifungal immunity and gut mycobiome imbalance with the largest possible 399 sample size. Although liver histology is considered the gold standard of MASLD diagnosis, the 400 more easily accessible TE is a widely used and validated technique that has shown a high 401 performance for the diagnosis and exclusion of advanced fibrosis when compared to liver 402 biopsy (45). Additionally, it reduces the imminent risk of sampling error due to heterogeneous 403 distribution of fibrosis when assessing liver biopsy specimens (46).

404 Clinical and anthropometric characteristics of the study cohort are shown in Table 2. A
405 cutoff for daily alcohol consumption was set (<20 g/d for female and <30 g/d for male subjects)</li>
406 and further underlying liver disease (e.g., autoimmune liver disease or chronic viral hepatitis)
407 was excluded. Information on patient's last antibiotic treatment was documented. Fecal, serum
408 and whole blood samples were immediately snap-frozen and stored in the local biobank.

#### 410 DNA extraction from blood and PBMCs and TaqMan SNP Genotyping

411 DNA was extracted from frozen blood or PBMC samples using the Roche High Pure PCR 412 Template Preparation Kit (Sigma Aldrich, #11796828001) according to the manufacturer's 413 instructions. Isolated DNA was then used in TaqMan SNP Genotyping Assays (ThermoFisher, CN #4351376; CARD9 (ID: C\_25956930\_20), CLEC7A (ID: C\_33748481\_10), IL-17A 414 415 rs2275913 (ID: C\_15879983\_10) according to manufacturer's instructions. Assays were conducted with the qTower<sup>3</sup> (Analytik Jena) and analyzed with the qPCRsoft 3.4 software 416 417 (Analytik Jena). The functionality of TaqMan SNP Genotyping was confirmed by additional 418 sequencing of 5% samples and validating the obtained genotypes. For sequencing, a 414 bp 419 IL17A amplified (5': of interest in the part gene was 420 ATATGATGGGAACTTGAGTAGTTTCCG, 3': CTCCTTCTGTGGTCACTTACGTGG) 421 with 2x Q5 polymerase master mix according to the manufacturer's instructions (NEB, 422 #M0492L). PCR samples were purified with the PCR & Gel Clean-Up Kit (Macherey-Nagel, 423 #740609.50) according to the manufacturer's instructions and sent to LGC genomics for 424 sequencing with the 5' primer. DNA sequences were evaluated with ApE (v.3.0.8).

#### 425 Fecal DNA extraction, internal transcribed spacer 1 and 16S rRNA sequencing

Microbial DNA was extracted from stool samples using the DNeasy PowerSoil Kit (Qiagen, 426 427 #12888-100) according to the manufacturer's instructions. We divided the sample into 4 428 subsamples to increase efficiency of the beat-beating step.

429 The Illumina platform Miseq V3 with paired-end reads of 300 bp was used for all 430 samples. For the ITS sequencing samples were processed by LGC Genomics GmbH. The ITS1 431 region was amplified using ITS1F/ITS2R primers. The total read count was on average 54,000

reads/sample. From the 246 total 16S rRNA sequencing samples, 149 16S rRNA sequencing
samples that had not been previously analyzed were processed by LGC Genomics GmbH using
sequencing primers 341F-785R, targeting the V3-V4 region. The total read count was on
average 56,000 reads/sample. 97 16S rRNA sequencing samples from a previous study were
processed as described in Rau et al (14).

#### 437 **Taxonomic profiling**

Taxonomic annotation of fungal Internal Transcribed Spacer (ITS) was performed using the PIPITS pipeline (47) version 2.4, with default parameters including quality filtering, read-pair merging, ITS1 extraction and chimera removal. Remaining reads were binned based on 97% similarity as operational taxonomic units (OTUs) and aligned with QIIME (48) to the UNITE fungi database (49) using mothur classifier. Samples were then normalized by cumulative sum scaling using the R package metagenomeSeq. Due to the complex fungal taxonomy, we grouped fungi according to genus but used the CTG species to characterize the *Candida* genus.

For the 16S rRNA sequencing data, quality control to remove low-quality reads and taxonomic annotation was performed using QIIME (48). Raw reads were joined and trimmed with cutadapt to remove the primer sequences. Deblur workflow was used for filtering and denoising the joined reads. Assigning taxonomic information to each amplicon sequence variant (ASV) was performed using a Naive Bayes classifier with 99% similarity in QIIME. The classifier was fitted to the appropriate rRNA gene region (V3-V4) with the SILVA 132 database (50).

#### 452 **Diversity analysis**

453 Alpha diversity indices detailing mycobiome community composition within samples were 454 calculated using the R package vegan. Testing for significant differences in alpha diversity was 455 performed using Wilcoxon rank-sum test. For estimating beta diversity reflecting community 456 dissimilarities, *cmultRepl* function from R package zCompositions was first used to perform 457 Bayesian-Multiplicative replacement of count zeros to the raw OTU table. Aitchison distances 458 were calculated using aDist function from the R package robCompositions. We performed 459 Partial Least Squares Discriminant Analysis (PLS-DA) using the mycobiome Aitchison 460 distance matrix with the R package mixOmics. To test for significant differences in the 461 mycobiome composition, permutational multivariate analysis of variance (PERMANOVA) as 462 implemented in the function adonis from R package vegan adjusting for age, gender, obesity-463 related parameters (age, gender, BMI, DM, aHT and hyperlipidemia) was used. Mycobiome 464 community and clinical data (age, gender, height, weight, BMI, AST and ALT) were fit onto 465 the ordination using the function *envfit* from vegan R package.

#### 466 **PBMC and T cell isolation**

467 Freshly drawn blood from healthy volunteers was diluted 1:1 in PBS / 1 mM EDTA (Invitrogen, 468 ThermoFisher Scientific, #AM9260G) containing 1% inactivated human AB serum (Sigma 469 Aldrich, #H4522-100ML) and separated via Biocoll density gradient medium (Bio&SELL, 470 #BS.L 6115) in SepMate tubes (Stemcell Technologies, #85460) according to the 471 manufacturer's instructions. Afterwards, PBMCs were washed 3 times with PBS-EDTA-472 human serum mix. As T cell proportions vary strongly between individual PMBC donors, we 473 additionally isolated T cells before stimulation.

474	T cells were isolated from freshly isolated PBMCs by negative selection with the human
475	Pan T Cell Isolation Kit (Miltenyi, #130-096-535) according to manufacturer's instructions and
476	the purity of >90% was assessed by flow cytometry (Miltenyi MACSQuant <sup>®</sup> ).

- 477 PBMC and T cell number and cell viability were measured directly after isolation with
- the LUNA automated cell counter (Logos Biosystems) and the viability was in each case >99%.

#### 479 **Preparation of fungal lysates**

480 50 ml inoculated YPD medium (20 g/L glucose, 20 g/L peptone, 10 g/L yeast extract) was 481 cultured overnight at 25 °C (D. hansenii CBS767) and 37 °C (C. albicans SC5314, N. glabratus 482 CBS138, C. parapsilosis ATCC22019, C. tropicalis PI941, S. cerevisiae AR#0400). The 483 overnight culture was diluted 1:50 in 50 ml YPD medium and cultured for another 5 h. Cells 484 were harvested by centrifugation at 4.000 g for 10 min and the cell pellet was resuspended in 485 lysis buffer (50mM Tris-HCl, 150 mM NaCl, 0.1 % Triton X-100, 1 mM DTT, 10 % glycerol) 486 with freshly adjusted proteinase inhibitor (Sigma, #S8820-20TAB). For lysis, 500 µl glass 487 beads were added per tube and five 1min vortexing steps were followed by five 1 min cooling 488 steps on ice. After centrifugation at 20.000 g for 5 min the supernatant was transferred to a fresh 489 reaction tube and stored in aliquots at -80 °C. The protein concentration was measured with the 490 Qubit protein assay kit (Invitrogen, ThermoFisher Scientific, #Q33211).

#### 491 *Ex vivo* **T** cell stimulation

Freshly isolated T cells were plated at  $2x10^6$  cells/well in 48-well plates and stimulated with 493 40 µg/ml fungal lysate or CTL-Test<sup>TM</sup> culture medium supplemented with PenStrep and L 494 glutamine as medium control, in a final volume of 500 µl. For control of effective T cell

functionality, wells were precoated with 1  $\mu$ g/ml anti-human CD3 antibody (Miltenyi, #130-093-387) at 37 °C for 2 h before addition of cells and medium. All samples were supplemented with 1  $\mu$ g/ml anti-human CD28 antibody (Miltenyi, #130-093-375). The plates were incubated for 48 h at 37 °C with 5 % CO2. All samples were prepared in duplicates. After incubation, supernatants were frozen at -80 °C until cytokine measurement.

#### 500 Quantification of cytokines by multiplex immunoassay

501 The secretion of cytokines (IL-17A, IFN- $\gamma$ , IL-22, TNF- $\alpha$ ) was assessed in supernatants of *ex* 502 *vivo* T cell stimulation assays using Luminex technology (ProcartaPlex<sup>TM</sup> Multiplex 503 Immunoassay, Thermo Fisher Scientific). The analyses were performed according to the 504 instructions from the manufacturer.

505

#### 506 IL-17A ELISA

507 Antigen-specific IL-17A levels were measured in thawed supernatants in duplicate using the 508 IL-17A ELISA kit (Invitrogen, ThermoFisher Scientific, #BMS2017) according to the 509 manufacturer's instructions. The standard curve was calculated from blank-curated mean 510 standard values with a 4-parameter curve fit (R package dr4pl, v2.0.0). All sample values were 511 blank-curated before concentration calculation via the standard curve formula.

#### 512 **Data visualization**

513 Figures were generated by R software 3.6.3, using ggplot2 package.

#### 514 Statistics

515 Associations between the SNP genotypes and fibroscan values or grouped fibrosis (cut-off 516 9.7kPa) were investigated with generalized linear models adjusting for age, BMI, gender and 517 PNPLA3 rs738409 with the glm function of the R package stats. Due to its potential as a genetic 518 risk factor for MASLD (22), we additionally adjusted for the PNPLA3 rs738409 genotype in 519 all SNP-based generalized linear model (glm) calculations. The PNPLA3 rs738409 genotyping 520 data was available for samples of our MASLD patient cohort data but were generated in a 521 previous study (23). Statistical analysis of this data with the *glm* function confirmed primary 522 findings from this study (Fig. 2C).

523 Correlations between mycobiome and clinical data were assessed by Spearman's 524 correlation adjusting for age, gender, and obesity-related parameters (age, sex, BMI, DM, aHT 525 and hyperlipidemia) using the function *pcor.test* from R package ppcor. Differentially abundant 526 genera were identified by the Wilcoxon rank-sum test using R package stats, and by a 527 generalized linear model adjusting for previously mentioned parameters (genus ~ 528 fibroscan.group + age + gender + BMI + DM + aHT + hyperlipidemia), with *glm* function from 529 R package stats. Association between the presence or absence of CTG species and the fibrosis 530 state was calculated by the Fisher test, using the *fisher.test* function from R package stats. A 531 generalized linear model adjusting for previously mentioned parameters was used to study the 532 association between CTG species and fibroscan value (genus ~ fibroscan + age + gender + BMI 533 + DM + aHT + hyperlipidemia), with *glm* function from R package stats. When exploring all 534 data, the antibiotic intake was included for adjustment when appropriate.

#### 536 Ethics approval & consent to participate

This study, involving the MASLD patient cohort (University of Würzburg: EK 96/12, 05.09.2012; EK 188/17, 13.01.2020) and healthy volunteers (University of Würzburg: EK 191/21, 16.08.2021) was approved by the local ethics committee and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. We obtained written informed consent from all patients and healthy volunteers included in this study.

542

#### 543 Data availability

Raw sequences from ITS1 gene sequencing were registered at NCBI under BioProjectPRJNA834619.

546

#### 547 AUTHOR CONTRIBUTIONS

548 O.K., A.G., T.D. and G.P. conceived and designed the study. A.G., H.M.H., and M.R. recruited 549 the participants and were responsible for clinical data collection. M.R. and H.M.H. collected 550 fecal samples and extracted DNA from feces together with N.T.. A.M.A. and M.H. collected 551 blood samples for the T cell stimulation assay, J.L. provided additional samples for this assay. 552 H.M.H. and N.T. extracted DNA from blood and PBMC samples. R.M., N.E.N. and A.M.A. 553 were involved in planning of experimental analyses. N.T. performed and analyzed the 554 experimental analyses. G.P., S.L.S., O.K. and M.H. were involved in planning of mycobiome 555 analysis. S.L.S. and M.M. performed the metagenomics analyses. K.H. and A.Sh. performed 556 the Luminex assays. A.Sch., N.R. and I.S.B. contributed to functional ex vivo assays. O.K.,

557 G.P., and A.G. led and supervised the research work. N.T. and S.L.S. wrote the manuscript.

558 O.K., A.G., G.P., R.M., K.H. and M.R. edited the manuscript. All authors reviewed and made

substantial contributions and approved the final version of the manuscript.

560

#### 561 ACKNOWLEDGMENTS

562 This project was funded by the IZKF Würzburg (project A-401), the Marie Sklodowska-Curie Actions (MSCA), and Innovative Training Networks, H2020-MSCA-ITN-2018, 813781 563 564 "BestTreat" and by funds from the Deutsche Forschungsgemeinschaft (DFG) within the Collaborative Research Center CRC 124 FungiNet (project C3 to O. Kurzai; project B2 to T. 565 566 Dandekar). GP would like to thank the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy and the Federal Ministry of 567 Education and Research (BMBF, Germany), under the project PerMiCCion (Project ID 568 569 01KD2101A). We want to thank Ina Gaube, Barbara Conrad, Carolin Spielau-Romer and Lea 570 Strobel for their contribution to this project.

571

#### 572 **DISCLOSURE OF INTEREST**

573 The authors report there are no competing interests to declare.

#### 574 **ABBREVIATIONS**

aHT: arterial hypertension, ALD: alcohol-associated liver disease, ALT: alanine
aminotransferase, AST: aspartate aminotransferase, BCAA: branched-chain amino acid, BS:
bland steatosis, *C. albicans: Candida albicans, D. hansenii: Debaryomyces hansenii*, glm:
generalized linear model, HC: healthy control, MAF: minor allele frequency, MASLD:

- 579 metabolic dysfunction-associated steatotic liver disease, MASH: metabolic dysfunction-
- 580 associated steatohepatitis, OTU: operational taxonomic unit, TE; transient elastography, rTreg:
- 581 resting regulatory T cells, S. cerevisiae: Saccharomyces cerevisiae, SCFA: short-chain fatty

582 acid

#### 583 REFERENCES

- 584 Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A 1. 585 multisociety Delphi consensus statement on new fatty liver disease nomenclature. J 586 Hepatol. 2023;79(6):1542-56.
- 587 2. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden 588 of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev 589 Gastroenterol Hepatol. 2018;15(1):11-20.
- 590 Friedman SL, Neuschwander-Tetri BA, Rinella M, and Sanyal AJ. Mechanisms of 3. 591 NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-22.
- 592 4. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, and Parks EJ. 593 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with 594 nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-51.
- 595 5. Buzzetti E, Pinzani M, and Tsochatzis EA. The multiple-hit pathogenesis of non-596 alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48.
- 597 Rau M, Schilling AK, Meertens J, Hering I, Weiss J, Jurowich C, et al. Progression 6. 598 from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher 599 Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell 600 Ratio in Peripheral Blood and in the Liver. J Immunol. 2016;196(1):97-105.
- 7. 601 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut-602 liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 603 2018;15(7):397-411.
- 604 Sharma S, and Tripathi P. Gut microbiome and type 2 diabetes: where we are and where 8. 605 to go? J Nutr Biochem. 2019;63:101-8.
- 606 9. Palmas V, Pisanu S, Madau V, Casula E, Deledda A, Cusano R, et al. Gut microbiota 607 markers associated with obesity and overweight in Italian adults. Sci Rep. 608 2021;11(1):5532.
- 609 10. Lang S, and Schnabl B. Microbiota and Fatty Liver Disease-the Known, the Unknown, 610 and the Future. Cell Host Microbe. 2020;28(2):233-44.
- Sharpton SR, Schnabl B, Knight R, and Loomba R. Current Concepts, Opportunities, 611 11. 612 and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty 613 Liver Disease. Cell Metab. 2021;33(1):21-32.
- Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, et al. Risk assessment with gut 614 12. 615 microbiome and metabolite markers in NAFLD development. Sci Transl Med. 616 2022;14(648):eabk0855.
- 617 Liu Y, Meric G, Havulinna AS, Teo SM, Aberg F, Ruuskanen M, et al. Early prediction 13. 618 of incident liver disease using conventional risk factors and gut-microbiome-augmented 619 gradient boosting. Cell Metab. 2022;34(5):719-30 e4.
- 620 Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, et al. Fecal 14. 621 SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a 622 putative link to systemic T-cell activation and advanced disease. United European 623 Gastroenterol J. 2018;6(10):1496-507.
- 624 Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, et al. The gut 15. 625 mycobiome of the Human Microbiome Project healthy cohort. Microbiome. 626 2017;5(1):153.
- Thielemann N, Herz M, Kurzai O, and Martin R. Analyzing the human gut mycobiome 627 16. 628 - A short guide for beginners. Comput Struct Biotechnol J. 2022;20:608-14.

- 629 17. Turner SA, and Butler G. The Candida pathogenic species complex. Cold Spring Harb 630 Perspect Med. 2014;4(9):a019778.
- 631 18. Bacher P, Hohnstein T, Beerbaum E, Rocker M, Blango MG, Kaufmann S, et al. Human 632 Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida 633 albicans. Cell. 2019;176(6):1340-55 e15.
- 634 19. Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, et al. The fecal mycobiome in non-alcoholic fatty liver disease. J Hepatol. 2022;76(4):788-99. 635
- 636 20. Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, et al. Candida albicans-637 specific Th17 cell-mediated response contributes to alcohol-associated liver disease. 638 Cell Host Microbe. 2023;31(3):389-404 e7.
- 639 21. Arslanow A, Stokes CS, Weber SN, Grunhage F, Lammert F, and Krawczyk M. The 640 common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by 641 controlled attenuation parameter (CAP). Liver Int. 2016;36(3):418-26.
- 642 Salari N, Darvishi N, Mansouri K, Ghasemi H, Hosseinian-Far M, Darvishi F, et al. 22. 643 Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver 644 disease: a systematic review and meta-analysis. BMC Endocr Disord. 2021;21(1):125.
- 645 23. Sarlos P, Kovesdi E, Magyari L, Banfai Z, Szabo A, Javorhazy A, et al. Genetic update 646 on inflammatory factors in ulcerative colitis: Review of the current literature. World J 647 Gastrointest Pathophysiol. 2014;5(3):304-21.
- 648 Borman AM, and Johnson EM. Name Changes for Fungi of Medical Importance, 2018 24. 649 to 2019. J Clin Microbiol. 2021;59(2).
- 650 25. Seelbinder B, Chen J, Brunke S, Vazquez-Uribe R, Santhaman R, Meyer AC, et al. Antibiotics create a shift from mutualism to competition in human gut communities 651 652 with a longer-lasting impact on fungi than bacteria. Microbiome. 2020;8(1):133.
- 653 26. Watts SC, Ritchie SC, Inouye M, and Holt KE. FastSpar: rapid and scalable correlation 654 estimation for compositional data. Bioinformatics. 2019:35(6):1064-6.
- 655 Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. 27. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness 656 657 Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty 658 Liver Disease. Gastroenterology. 2019;156(6):1717-30.
- 659 Butler G, Rasmussen MD, Lin MF, Santos MA, Sakthikumar S, Munro CA, et al. 28. 660 Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature. 661 2009;459(7247):657-62.
- 662 29. Ramos-Moreno L, Ruiz-Perez F, Rodriguez-Castro E, and Ramos J. Debaryomyces 663 hansenii Is a Real Tool to Improve a Diversity of Characteristics in Sausages and Dry-664 Meat Products. *Microorganisms*. 2021;9(7).
- Loomba R, Friedman SL, and Shulman GI. Mechanisms and disease consequences of 665 30. 666 nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-64.
- 31. McGeachy MJ, Cua DJ, and Gaffen SL. The IL-17 Family of Cytokines in Health and 667 Disease. Immunity. 2019;50(4):892-906. 668
- 669 32. Conti HR, and Gaffen SL. IL-17-Mediated Immunity to the Opportunistic Fungal 670 Pathogen Candida albicans. J Immunol. 2015;195(3):780-8.
- Ramani K, and Biswas PS. Interleukin-17: Friend or foe in organ fibrosis. Cytokine. 671 33. 672 2019;120:282-8.
- 673 34. Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, et al. Fungal 674 microbiota dysbiosis in IBD. Gut. 2017;66(6):1039-48.
- 675 Hartmann P, Lang S, Zeng S, Duan Y, Zhang X, Wang Y, et al. Dynamic Changes of 35. 676 the Fungal Microbiome in Alcohol Use Disorder. Front Physiol. 2021;12:699253.

- 36. Shao TY, Ang WXG, Jiang TT, Huang FS, Andersen H, Kinder JM, et al. Commensal
- 677 36. Shao TY, Ang WXG, Jiang TT, Huang FS, Andersen H, Kinder JM, et al. Commensal
  678 Candida albicans Positively Calibrates Systemic Th17 Immunological Responses. *Cell*679 *Host Microbe*. 2019;25(3):404-17 e6.
- 680 37. Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, et al. The Candida albicans
  681 exotoxin candidalysin promotes alcohol-associated liver disease. *J Hepatol.*682 2020;72(3):391-400.
- 683 38. Li XV, Leonardi I, Putzel GG, Semon A, Fiers WD, Kusakabe T, et al. Immune
  684 regulation by fungal strain diversity in inflammatory bowel disease. *Nature*.
  685 2022;603(7902):672-8.
- Brunke S, and Hube B. Two unlike cousins: Candida albicans and C. glabrata infection
  strategies. *Cell Microbiol.* 2013;15(5):701-8.
- 688 40. Ochangco HS, Gamero A, Smith IM, Christensen JE, Jespersen L, and Arneborg N. In
  689 vitro investigation of Debaryomyces hansenii strains for potential probiotic properties.
  690 World J Microbiol Biotechnol. 2016;32(9):141.
- 41. Jain U, Ver Heul AM, Xiong S, Gregory MH, Demers EG, Kern JT, et al.
  Debaryomyces is enriched in Crohn's disease intestinal tissue and impairs healing in mice. *Science*. 2021;371(6534):1154-9.
- Frau A, Kenny JG, Lenzi L, Campbell BJ, Ijaz UZ, Duckworth CA, et al. DNA
  extraction and amplicon production strategies deeply inf luence the outcome of gut
  mycobiome studies. *Sci Rep.* 2019;9(1):9328.
- 697 43. Chu H, Duan Y, Yang L, and Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. *Gut.* 2019;68(2):359-70.
- Guinan J, Wang S, Hazbun TR, Yadav H, and Thangamani S. Antibiotic-induced decreases in the levels of microbial-derived short-chain fatty acids correlate with increased gastrointestinal colonization of Candida albicans. *Sci Rep.* 2019;9(1):8872.
- Tovo CV, Villela-Nogueira CA, Leite NC, Panke CL, Port GZ, Fernandes S, et al.
  Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD). *Ann Hepatol.* 2019;18(3):445-9.
- 46. European Association for Study of L, and Asociacion Latinoamericana para el Estudio
  del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of
  liver disease severity and prognosis. *J Hepatol.* 2015;63(1):237-64.
- 47. Gweon HS, Oliver A, Taylor J, Booth T, Gibbs M, Read DS, et al. PIPITS: an automated
  pipeline for analyses of fungal internal transcribed spacer sequences from the Illumina
  sequencing platform. *Methods Ecol Evol.* 2015;6(8):973-80.
- 48. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al.
  QIIME allows analysis of high-throughput community sequencing data. *Nat Methods*.
  2010;7(5):335-6.
- Nilsson RH, Larsson KH, Taylor AFS, Bengtsson-Palme J, Jeppesen TS, Schigel D, et
  al. The UNITE database for molecular identification of fungi: handling dark taxa and
  parallel taxonomic classifications. *Nucleic Acids Res.* 2019;47(D1):D259-D64.
- 717 50. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA
  718 ribosomal RNA gene database project: improved data processing and web-based tools.
  719 *Nucleic Acids Res.* 2013;41(Database issue):D590-6.
- 720

## 721 FIGURES



723 Fig. 1| Flow diagram with an overview of the study participants.



725 Fig. 2| The IL17A rs2275913 genotype is associated with liver stiffness in MASLD. A) Violin Plot for visualization of IL17A genotype association with fibrosis as assessed by 726 fibroscan. Statistical comparison was performed using Kruskal-Wallis Test (pKruskal-Wallis) and 727 728 generalized linear models adjusted for age, gender, BMI, PNPLA3 rs738409 genotype (pglm) 729 based on fibroscan cut-off=9.7 kPa. B) Allelic discrimination Plot after TaqMan SNP 730 Genotyping. C) Violin Plot for visualization of known PNPLA3 risk variant rs738409 731 association with fibrosis as assessed by fibroscan. Statistical comparison was performed using 732 Kruskal-Wallis Test (pKruskal-wallis) and generalized linear models adjusted for age, gender and 733 BMI (p<sub>glm</sub>) based on fibroscan cut-off=9.7kPa.



## 735 Fig. 3| Mycobiome changes in the different diagnosed groups and healthy controls and 736 microbial community network. A) Beta diversity. PLS-DA of Aitchison distance of the 737 mycobiome composition by diagnosis. **B**) Overview of mycobiome composition at genus level 738 in MASLD, BS, MASH, and HC groups. C) Boxplot of Saccharomyces and Penicillium 739 abundances. Statistical comparison between groups (HC, BS, MASH, and MASLD) was 740 performed using Wilcoxon rank-sum test (pwilcoxon) and generalized linear models adjusting for 741 age, gender and obesity-related parameters (p<sub>glm</sub>). **D**) Microbial community network showing 742 the 4 subcommunity modules. Significant negative correlations are shown in blue and positive 743 in red. The module significantly associated with MASLD-related parameters is shown with red 744 nodes and significant correlations between the genera and fibroscan, AST, ALT, and GGT are 745

746

shown in green.



748 Mycobiome changes by fibroscan-based fibrosis groups. A) Beta diversity. PLS-DA of 749 Aitchison distance of the mycobiome composition by fibrosis stage group. B) Overview of 750 mycobiome composition at genus level in early and advanced fibrosis groups (fibroscan cut-751 off </>9.7 kPa). C) Boxplot of CTG species abundances. Statistical comparison between early 752 and advanced fibrosis was performed using Wilcoxon rank-sum test (pwilcoxon) and generalized 753 linear models adjusting for age, gender and obesity-related parameters (p<sub>glm</sub>).

747



754





Fig. 6| Elevated Th17/rTreg ratios in MASH patients carrying the IL17A rs2275913 minor 768 769 allele. A) Th17/rTreg ratios in blood samples of healthy controls and MASLD patients included 770 in this study (HC: n=28, BS: n=10, MASH: n=31 and MASLD: n=17). B) Th17/rTreg ratios 771 in MASH patients according to *IL17A* rs2275913 genotype (G/G: n=13, A/G: n=14, A/A: 772 n=4). Statistical comparisons were performed using Kruskal-Wallis Test (P<sub>Kruskal-Wallis</sub>) and T 773 test comparing mean Th17/rTreg ratios using HC as a reference group (A) and between IL17A 774 rs2275913 genotypes (**B**). Horizontal lines in the boxplots indicate from top to bottom 75th percentile, median and 25th percentile. Whiskers display minimum and maximum values in 775 776 1.5x the interquartile range. Dots specify individuals for the three *IL17A* rs2275913 genotypes.

# 777 TABLES WITH TITLES AND LEGENDS

## 778 **Table 1** Cytokine levels after ex vivo stimulation of T cells from *IL17A* rs2275913-genotyped

donors with *C. albicans*, *D. hansenii & S. cerevisiae*. Values are shown as means and range.

	C. albicans			D. hansenii			S. cerevisiae		
	<b>G/G</b> n = 9	A allele carrier n = 18	р	<b>G/G</b> n = 9	A allele carrier n = 17	р	<b>G/G</b> n = 6	A allele carrier n = 11	р
IFN- γ	240.3 (0-1661)	1411.0 (0-4825)	0.199	169.3 (0-717.2)	1902.9 (0-7833)	0.019	46.8 (0-211.2)	1290.8 (0-6155.3)	0.339
IL-17A	17.1 (0-49.0)	100.2 (0-680.9)	0.169	10.1 (0-45.7)	98.8 (0-635.6)	0.057	3.4 (0-20.2)	66.2 (0-315.0)	0.264
IL-22	52.1 (0-185.7)	253.5 (0-1275)	0.066	22.2 (0-95.8)	206.4 (0-1038)	0.137	4.5 (21.3)	126.3 (0-648.2)	0.174
TNF-α	29.7 (0-79.2)	181.0 (0-861.1)	0.127	1.6 (0-7.2)	94.2 (0-405.7)	0.028	2.4 (0-11.4)	48.8 (0-282.9)	0.465

#### 781 Table 2| MASLD patient cohort characteristics. Values are shown as means and range.

	MASLD patients	healthy controls	
	(n=451)	(n=31)	
general information		•	
male	n=166 (37.5%)	n=15 (48.4%)	
female	n=277 (62.5%)	<i>n</i> =16 (51.6%)	
age (years)	46.5 (18-73), <i>n</i> =451	27.3 (23-37), <i>n</i> =31	
$BMI (kg/m^2)$	46.2 (21.6-78.2), <i>n</i> =450	21.4 (17.5-30), <i>n</i> =31	
underweight: (<18.5)	n=0	<i>n</i> =4 (12.9%)	
normal: (18.5-24.9)	n=9(2%)	<i>n=23</i> (74.2%)	
overweight: (25-29.9)	n=45 (10%)	n=3 (9.7%)	
obese – type I: (30-34.9)	n=31 (7%)	<i>n</i> =1 (3.2%)	
obese – type II: (35-39.9)	n=29 (6.5%)	n=0	
obese – type III: (>40)	<i>n=336</i> (74.5%)	n=0	
liver function tests			
AST (U/L)	36.8 (11-249), <i>n</i> =450	20.5 (11.6-45.6), <i>n</i> =27	
ALT (U/L)	49.4 (5.8-469.7), <i>n</i> =451	18.5 (10-46.6), <i>n</i> =28	
γ-GT (U/L)	65.2 (7.6-914), <i>n</i> =450	NA	
AP (U/L)	77.2 (0-222), <i>n</i> =450	NA	
AST/ALT ratio	0.9 (0.2-3.7), n=450	1.2 (0.6-1.6), <i>n</i> =27	
glucose (mg/dl)	111.2 (70-444), <i>n</i> =430	NA	
lipid metabolism			
cholesterol (mg/dl)	187.5 (22-342), <i>n</i> =419	NA	
triglyceride (mg/dl)	166.8 (31-1188), <i>n</i> =419	NA	
elastography			
fibroscan (kPa)	11.6 (1.8-75), <i>n</i> =350	NA	
CAP (dB/m)	346.5 (40-400), <i>n</i> =258	NA	